These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15095852)

  • 21. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
    Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
    Hanauer S; Sandborn WJ; Persson A; Persson T
    Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.
    Levine A; Kori M; Dinari G; Broide E; Shaoul R; Yerushalmi B; On A; Bujanover Y; Pröls M; Greinwald R;
    Inflamm Bowel Dis; 2009 Jul; 15(7):1055-61. PubMed ID: 19229988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.
    Löfberg R; Danielsson A; Suhr O; Nilsson A; Schiöler R; Nyberg A; Hultcrantz R; Kollberg B; Gillberg R; Willén R; Persson T; Salde L
    Gastroenterology; 1996 Jun; 110(6):1713-8. PubMed ID: 8964395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budesonide for Crohn's disease.
    Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
    Löfberg R; Ostergaard Thomsen O; Langholz E; Schiöler R; Danielsson A; Suhr O; Graffner H; Påhlman L; Matzen P; Møller-Petersen JF
    Aliment Pharmacol Ther; 1994 Dec; 8(6):623-9. PubMed ID: 7696452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budesonide for induction of remission in Crohn's disease.
    Seow CH; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH
    Cochrane Database Syst Rev; 2008 Jul; (3):CD000296. PubMed ID: 18646064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease.
    van Ierssel GJ; van der Sluys Veer A; Verspaget HW; Griffioen G; van Hogezand RA; Lamers CB
    Immunopharmacology; 1995 Feb; 29(1):11-7. PubMed ID: 7768667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.
    Spencer CM; McTavish D
    Drugs; 1995 Nov; 50(5):854-72. PubMed ID: 8586030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
    Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.
    D'Haens G; Verstraete A; Cheyns K; Aerden I; Bouillon R; Rutgeerts P
    Aliment Pharmacol Ther; 1998 May; 12(5):419-24. PubMed ID: 9663720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.
    Steinhart AH; Feagan BG; Wong CJ; Vandervoort M; Mikolainis S; Croitoru K; Seidman E; Leddin DJ; Bitton A; Drouin E; Cohen A; Greenberg GR
    Gastroenterology; 2002 Jul; 123(1):33-40. PubMed ID: 12105831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.
    Löfberg R; Rutgeerts P; Malchow H; Lamers C; Danielsson A; Olaison G; Jewell D; Ostergaard Thomsen O; Lorenz-Meyer H; Goebell H; Hodgson H; Persson T; Seidegård C
    Gut; 1996 Jul; 39(1):82-6. PubMed ID: 8881815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effectiveness of budesonide therapy for Crohn's disease.
    Kane SV; Schoenfeld P; Sandborn WJ; Tremaine W; Hofer T; Feagan BG
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1509-17. PubMed ID: 12182751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
    de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
    Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
    Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
    Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
    Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.